VTYX (Ventyx Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VTYX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | ALLISON HULME | Director | D | — | — |
| 2026-03-04 | Roy Gonzales | Senior VP, Finance | D | — | — |
| 2026-03-04 | Onaiza Cadoret-Manier | Director | D | — | — |
| 2026-03-04 | John Nuss | CHIEF SCIENTIFIC OFFICER | D | — | — |
| 2026-03-04 | William Richard White | Director | D | — | — |
| 2026-03-04 | Matthew Richard Moore | Chief Operating Officer | D | — | — |
| 2026-03-04 | Somu Subramaniam | Director | D | — | — |
| 2026-03-04 | Raju Mohan | CEO AND PRESIDENT | D | — | — |
| 2026-03-04 | Mark S Forman | Chief Medical Officer | D | — | — |
| 2026-03-04 | SHEILA GUJRATHI | Director | D | — | — |
| 2026-03-03 | Somu Subramaniam | Director | J | — | — |
| 2025-12-19 | John Nuss | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2025-12-19 | Raju Mohan | CEO AND PRESIDENT | MIXED | — | — |
| 2025-11-19 | Roy Gonzales | Senior VP, Finance | A | — | — |
| 2025-11-19 | Mark S Forman | Chief Medical Officer | A | — | — |
| 2025-06-06 | William Richard White | Director | A | — | — |
| 2025-06-06 | Sheila Gujrathi | Director | A | — | — |
| 2025-06-06 | Onaiza Cadoret-Manier | Director | A | — | — |
| 2025-06-06 | ALLISON HULME | Director | A | — | — |
| 2025-06-06 | Somu Subramaniam | Director | A | — | — |
| 2025-05-16 | Roy Gonzales | Senior VP, Finance | A | — | — |
| 2025-05-16 | Mark S Forman | Chief Medical Officer | A | — | — |
| 2025-04-03 | John Nuss | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-04-01 | Raju Mohan | CEO AND PRESIDENT | M | — | — |
| 2025-04-01 | John Nuss | CHIEF SCIENTIFIC OFFICER | M | — | — |
| 2025-04-01 | Somu Subramaniam | Director | J | — | — |
| 2025-03-12 | Somu Subramaniam | Director | J | — | — |
| 2025-01-03 | Matthew Richard Moore | Chief Operating Officer | A | — | — |
| 2025-01-03 | John Nuss | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-01-03 | Mark S Forman | Chief Medical Officer | A | — | — |
| 2025-01-03 | Roy Gonzales | Senior VP, Finance | A | — | — |
| 2025-01-03 | Raju Mohan | CEO AND PRESIDENT | A | — | — |
| 2024-12-30 | John Nuss | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2024-12-26 | Sheila Gujrathi | Director | Buy | — | — |
| 2024-12-19 | John Nuss | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2024-12-19 | Raju Mohan | CEO AND PRESIDENT | M | — | — |
| 2024-12-11 | John Nuss | CHIEF SCIENTIFIC OFFICER | M | — | — |
| 2024-11-25 | Raju Mohan | CEO AND PRESIDENT | Buy | — | — |
| 2024-08-13 | Mark S Forman | Chief Medical Officer | A | — | — |
| 2024-06-26 | Somu Subramaniam | Director | J | — | — |
| 2024-06-26 | NSV Partners III GP LLC | 10%+ Owner | J | — | — |
| 2024-06-11 | Raju Mohan | CEO AND PRESIDENT | M | — | — |
| 2024-06-07 | Onaiza Cadoret-Manier | Director | A | — | — |
| 2024-06-07 | Sheila Gujrathi | Director | A | — | — |
| 2024-06-07 | William Richard White | Director | A | — | — |
| 2024-06-07 | ALLISON HULME | Director | A | — | — |
| 2024-06-07 | Somu Subramaniam | Director | A | — | — |
| 2024-05-17 | Matthew Richard Moore | Chief Operating Officer | A | — | — |
| 2024-04-16 | NSV Partners III GP LLC | 10%+ Owner | J | — | — |
| 2024-04-16 | Somu Subramaniam | Director | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 16,892,528 | — |
| — | 10%+ Owner | 15,659,835 | — |
| — | 10%+ Owner | 8,439,635 | — |
| — | 10%+ Owner | 4,699,036 | — |
| — | Director | 3,684,769 | — |
| — | — | 1,410,303 | — |
| — | CHIEF BUSINESS OFFICER | 284,999 | — |
| — | See Remarks | 84,483 | — |
| — | CHIEF FINANCIAL OFFICER | 24,303 | — |
| — | Director | 7,027 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VTYX quote page; the site-wide leaderboard is on the insider transactions hub.